$1,700.0 billion for health reform

29 March 2009

The Lewin Group, a US consulting and policy analysis firm, has estimated at between $1,500.0 billion and 1,700.0 billion the cost of changing  the US health care system according to President Barack Obama's  election promises. However, this is likely to be an underestimate,  given that spending bills going through Congress have attracted  sizeable additional "earmarks," or supplementary commitments that are  often unrelated to the issue being voting on. Pres Obama is reported to  be considering a legislative device, the budget reconciliation process,  to prevent opposition Republicans from amending or blocking the reform  program.

So far, Pres Obama has committed to finding the first $634.0 billion  installment, which supporters hope will lead to universal health care  insurance coverage. The Pharmaceutical Research and Manufacturers of  America (PhRMA) supports the President's initiative, although this  may come at the cost of several measures that are detrimental to its  members: patent reform; price controls imposed on Medicare Part D  prescription drug purchases; the legalization of parallel trade; and a  follow-on biotechnology review pathway that is unfavorable to  brand-name companies (see page 13).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight